Results 141 to 150 of about 30,666,235 (182)

Residual HIV activity and host immunometabolic remodeling during antiretroviral therapy: implications for cardiovascular-kidney-metabolic risk. [PDF]

Front Immunol
Zhang J, Li X, Chen C, Wu Z, Qin F, Li Y, Zhang Y, Ning C.   +7 more
europepmc   +1 more source

Beyond Efficacy: The Access, Delivery Systems, Acceptability, Persistence, and Transition Management "ADAPT" Framework for Long-Acting Injectable PrEP in Sub-Saharan Africa. [PDF]

HIV AIDS (Auckl)
Ikoona EN, Namulemo L, Kaluya R, Ikoona R, Sahr F.   +4 more
europepmc   +1 more source

Beyond Oncology: Exploring the Expanding Role of CAR T Cell Therapy in Autoimmune and Infectious Diseases-A Systematic Review. [PDF]

Pathophysiology
Zaher K, Alrahimi J.
europepmc   +1 more source

Targeting the JAK/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation. [PDF]

Front Immunol
Garnier N, Ossi J, Marconi VC, Schinazi RF, Titanji BK.   +4 more
europepmc   +1 more source

HIV Reservoirs in Brain parenchyma and Cerebrospinal Fluid During Suppressive ART: Same-Same or Very Different? [PDF]

Curr HIV/AIDS Rep
Angelovich TA, Jamal Eddine J, Chalmers EK, Byrnes SJ, Churchill MJ.   +4 more
europepmc   +1 more source

Persistence of HIV-1 transmitted drug resistance mutations. [PDF]

Journal of Infectious Diseases, 2013
There are few data on the persistence of individual human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) mutations in the absence of selective drug pressure. We studied 313 patients in whom TDR mutations were detected at their first resistance test and who had a subsequent test performed while ART-naive.
Chloe Orkin, Kate Templeton, Brendan Payne   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Senotherapeutics and HIV-1 Persistence

Current HIV/AIDS Reports, 2020
To review the potential use of senotherapeutics, pharmacologic agents that target senescent cells, in addressing HIV-1 persistence.Treated HIV-1 infection results in a state of immune exhaustion, which may involve reprogramming of infected and bystander cells toward a state of cellular senescence.
Matthew A, Szaniawski, Adam M, Spivak
openaire   +2 more sources

Immune privilege and HIV‐1 persistence in the CNS

Immunological Reviews, 2006
Summary:  Human immunodeficiency virus‐1 (HIV‐1) neuroinvasion occurs early (during period of initial viremia), leading to infection of a limited amount of susceptible cells with low CD4 expression. Protective cellular and humoral immunity eliminate and suppress viral replication relatively quickly due to peripheral immune responses and the low level ...
Yuri, Persidsky, Larisa, Poluektova
openaire   +2 more sources